Sana Biotechnology sets sights on growth after $587.5M IPO
Following a banner year for Sana Biotechnology, which saw the company bring in one of the largest IPOs in biotech history, CEO Steve Harr is setting his sights on recruitment. Currently employing around 300 people across Seattle, San Francisco and Boston, Sana expects to grow that number to 400 by the end of the year. The key to the company’s success? Finding and hiring great people.
“One of the real benefits of Seattle is that the people in the life sciences are generally pretty happy here. It’s one of the reasons why the region has an outsized impact relative to the amount of capital it’s raised…the people who are here are really quite good.”